Novartis Announces Approval Of Itvisma In Europe For Spinal Muscular Atrophy

Novartis said the European Commission approved Itvisma (onasemnogene abeparvovec) for children aged 2+ plus teens and adults with 5q spinal muscular atrophy (biallelic survival motor neuron mutation). The EU label expansion is a meaningful positive regulatory milestone that supports commercial upside for the therapy and can improve market perception of Novartis’ biotech pipeline.

Analysis

Novartis said the European Commission approved Itvisma (onasemnogene abeparvovec) for children aged 2+ plus teens and adults with 5q spinal muscular atrophy (biallelic survival motor neuron mutation). The EU label expansion is a meaningful positive regulatory milestone that supports commercial upside for the therapy and can improve market perception of Novartis’ biotech pipeline.